Latest News from The Lab

Dasatinib, a Promising Anti-BCSC Agent in Combination with Paclitaxel to Overcome Chemotherapy Resistance in TNBCsOctober 02, 2018

We identified Dasatinib, a Src kinase family inhibitor, potently reduced BCSC self-renewal and two BCSC populations (ALDH+ and CD24lowCD44high) as well as phosphor-Src. We also demonstrated Dasatinib to block pac-induced BCSC enrichment and Src activation in the parental TNBC cells. Interestingly, we found that Dasatinib induced an epithelial differentiation of pac-resistant cells, resulting in…

Keep Reading →

International Drug Discovery and Development Forum 2018September 30, 2018

The Drug Discovery and Development Forum 2018 will highlight New Trends in Drug Discovery: Small Molecule Approaches to Immunotherapy and Drug Conjugates. When: October 22nd - 24th, 2018 Where: Centre for Translational Biology McGill University Health Centre, 1001 Decarie Boulevard, Bloc E, Montreal, Quebec H4A 3J1 For more information, please contact us at : (514)934-1934 ext. 7643…

Keep Reading →

New Marker and Potential Therapy for Triple Negative Breast CancersOctober 19, 2016

“Our study highlights new roles for CDK4 in regulating cancer stemness and as a novel prognostic marker in TNBC,” says Dr. Lebrun. Because the TNBC tumours are enriched with cancer stem cells – cells that utilize their self-renewal ability to generate and persistently propagate a heterogeneous tumor which results in metastasis and cancer relapse, while also displaying resistance to chemotherapy…

Keep Reading →

Le scalpel du XXIe siècleFebruary 17, 2012

L'équipe de Michel Meunier, de l'École polytechnique de Montréal, a mis au point un nouveau scalpel intégrant les plus récentes technologies du XXIe siècle, telles qu'un laser à impulsions ultracourtes et des nanoparticules, et qui permet de pratiquer des incisions de quelques centaines de nanomètres (10-9 mètre) dans les tissus humains. En collaboration avec Jean-Jacques Lebrun, du Centre de…

Keep Reading →